

# ICARE 2016

---

**Rationale for Scientific & Policy session: What can we do to improve outcomes in the next five years?**

Leveraging existing quality improvement & information sciences for greater application in epilepsy

*Jeffrey Buchhalter MD, PhD*

**April 14, 2016**

# Disclosures

---

- No conflict of interests related to this presentation
- A very, very frustrated clinical pediatric epileptologist

## Prevalence of Epilepsy in the USA

---

- The number of people with epilepsy, using prevalence numbers, ranges from [1.3 million to 2.8 million](#) (or 5 to 8.4 for every 1,000 people).
- The estimate currently thought to be most accurate is 2.2 million people or [7.1 for every 1,000 people](#).
- However, higher numbers of people report that they have active epilepsy, [8.4 out of 1,000 people](#). These numbers are even higher when people are asked if they have ever had epilepsy (called lifetime prevalence). 16.5 per 1,000 people reported that they had epilepsy at some point in their life.

1968

---

**THE PROGNOSIS OF  
PATIENTS WITH EPILEPSY**

By

**ERNST A. RODIN, M.D.**

*Chief of Neurology and Electroencephalography  
Lafayette Clinic  
Director of Medical Research  
Michigan Epilepsy Center  
Director of EEG Laboratory  
Childrens Hospital of Michigan  
Associate Professor, Department of Neurology  
Wayne State University  
Detroit, Michigan*

But let us return to the quotation that “80 to 85 per cent of all patients with epilepsy can be controlled.” Where did these figures originate? They are probably taken from a paper published in 1952 by Yahr et al. who stated in their summary that “The use of diphenylhydantoin (Dilantin) sodium and phenobarbital in this group of 319 patients resulted in 79 per cent control or improvement of seizures regardless of causation. The addition of other anticonvulsants added 6 per cent, giving an overall rate of 85 per cent improvement or control.”

## Prognosis- Recent Times

---

“In spite of medical therapy, seizures persist in approximately 20 percent of patients with primary generalized epilepsy and 35 percent of those with partial epilepsy.”

Devinsky, **1999**;NEJM;340(20), 1565

“Unfortunately, in 20–30% of patients, epilepsy cannot be controlled.”

Schmidt, **2009**;Epilepsy & Behavior;(15)56-65

## Prognosis- 2016

---

- No change in the population-based estimates of control (20-35%)
- Recognition that *prognosis in individual groups much worse*
  - Dravet
  - Epileptic spasms
  - Lennox-Gastaut
  - Symptomatic causes with intellectual disability

## Treatments- 2016

---

- Anti Seizure Drugs:
  - No significant improvement in efficacy
  - Improvements in tolerability
  - Limited added efficacy beyond first or second
- Surgery: under-utilized
- Dietary/metabolic:
  - Under-utilized
  - Under development
- Devices:
  - Efficacy equivalent to ASDs
  - Under development

## Consequences of intractable seizures

---

- Accidents: falls, burns
- Aspiration
- Cognitive decline
- Psychiatric/behavioral co-morbidities: ADHD, depression, suicide
- Social isolation
- Unemployment
- Premature mortality including SUDEP (second largest cause of years of life lost<sup>#</sup>)
- Costs to society: costs of care (\$12.5 B, 1995, intractable\*) & lost human potential

<sup>#</sup>Thurman 2014

\*Begley 2000



# Response?

---

- Depression?
- Cynicism?
- Aggressive optimism


# Status of Epilepsy Research




[undergradtutorialblog.blogspot.com](http://undergradtutorialblog.blogspot.com)



[www.ifmelranthetoo.com](http://www.ifmelranthetoo.com)



[cmtk.org](http://cmtk.org)



[pharmrev.aspetjournals.org](http://pharmrev.aspetjournals.org)



[web.stanford.edu](http://web.stanford.edu)

# Status of Epilepsy Research

---




## ⊥ Potential Responses in the Near Term

---

- What about the patients who are suffering now? Dying now?
- Can we find strategies that have been demonstrated to improve outcomes in the short term?
- Can we supplement our research strategies to focus on meaningful outcomes for patients?
- Can we leverage existing resources for this purpose?

## ⊥ Potential Responses in the Near Term

---

- What about the patients who are suffering now? Dying now?
- Can we find strategies that have been demonstrated to improve outcomes in the short term? 
- Can we supplement our research strategies to focus on meaningful outcomes for patients?
- Can we leverage existing resources for this purpose?

## What Can We Do Until Then?

---

- Adopt strategies known to reduce morbidity, mortality, and, when possible, reduce costs
- Implement meaningful, large scale data aggregation
  - Common definitions & data elements
  - Harmonize & Organize knowledge in a logical manner (ontologies)
  - Leverage the accumulated Big Data to inform personalized medicine
- Incentivize health system behavior that rewards active participation in improving outcomes for patients

# What is the Evidence that “Organized” Care Makes a Difference

---

## The 100 000 Lives Campaign: Setting a Goal and a Deadline for Improving Health Care Quality

Berwick DM. JAMA 295:324–327, Jan.18, 2006.

## The 100,000 Lives Campaign: A Scientific and Policy Review

Robert M. Wachter, M.D.  
Peter J. Pronovost, M.D., Ph.D.

*The authors were invited by the Journal to prepare a commentary on the Institute for Healthcare Improvement's 100,000 Lives Campaign, which had recently observed the end of its initial 18-month effort.*



On December 14, 2004, Dr. Don Berwick, the well-respected founder and chief executive offi-

### Article-at-a-Glance

**Background:** On June 14, 2006, the Institute for Healthcare Improvement (IHI) announced that its campaign to save 100,000 lives had far surpassed its goal—by saving 122,300 lives.

## More Evidence

---

Intensive Care Med (2010) 36:222–231  
DOI 10.1007/s00134-009-1738-3

ORIGINAL

Mitchell M. Levy  
R. Phillip Dellinger  
Sean R. Townsend  
Walter T. Linde-Zwirble  
John C. Marshall  
Julian Bion  
Christa Schorr

**The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis**

- N = 15,000
- 2 yrs
- Mortality reduced 6.2%
- 930 people

World J Surg (2009) 33:1075–1086  
DOI 10.1007/s00268-009-9959-8

---

**Establishing the Evidence Base for Trauma Quality Improvement: A Collaborative WHO-IATRIC Review**

Catherine J. Juillard · Charles Mock ·  
Jacques Goosen · Manjul Joshipura ·  
Ian Civil

- 34/36 articles reduced morbidity or mortality



# Stroke

---

## Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack

Lee H. Schwamm, MD; Gregg C. Fonarow, MD; Mathew J. Reeves, PhD; Wenqin Pan, PhD; Michael R. Frankel, MD; Eric E. Smith, MD, MPH; Gray Ellrodt, MD; Christopher P. Cannon, MD; Li Liang, PhD; Eric Peterson, MD, MPH; Kenneth A. LaBresh, MD

**Background**—Adherence to evidence-based guidelines for treatment of stroke or transient ischemic attack is suboptimal. We sought to establish whether participation in Get With the Guidelines–Stroke was associated with improvements in adherence.

**Methods and Results**—This prospective, nonrandomized, national quality improvement program measured adherence to guideline recommendations in 322 847 hospitalized patients discharged with a diagnosis of ischemic stroke or transient ischemic attack. A volunteer sample of 790 US academic and community hospitals participated from 2003 through 2007. The main outcome measures were change in adherence over time to 7 prespecified performance measures and a

## What Can We Do Until Then?

---

- Adopt strategies known to reduce morbidity, mortality, and, when possible, reduce costs
- Implement meaningful, large scale data aggregation
  - Common definitions & data elements
  - Harmonize & Organize knowledge in a logical manner (ontologies)
  - Leverage the accumulated Big Data to inform personalized medicine
- Incentivize health system behavior that rewards active participation in improving outcomes for patients

# Glossary of Descriptive Terminology for Ictal Semiology: Report of the ILAE Task Force on Classification and Terminology

---



- Table of Contents
  - General Terms
  - Terms for describing epileptic seizure semiology
    - Motor
    - Non-Motor
    - Autonomic
    - Somatotopic modifiers
    - Modifiers & descriptors of seizure timing
    - Duration
    - Severity!!

## SPECIAL REPORT

### Common data elements in epilepsy research: Development and implementation of the NINDS epilepsy CDE project

\*†David W. Loring, ‡Daniel H. Lowenstein, ‡§Nicholas M. Barbaro, ¶Brandy E. Fureman, ¶Joanne Odenkirchen, ¶Margaret P. Jacobs, \*\*Joan K. Austin, ††††Dennis J. Dlugos, §§Jacqueline A. French, ¶¶William Davis Gaillard, \*\*\*Bruce P. Hermann, †††Dale C. Hesdorffer, †††Steven N. Roper, §§§¶¶¶Anne C. Van Cott, \*\*\*Stacie Grinnon, and \*\*\*Alexandra Stout

Like the development of the Terminology Glossary, very thoughtful work has already been done for Common Data Elements

The challenge/opportunity is to take this work and adapt it to clinical epilepsy care

## Need to harmonized & organize terms & concepts

---

- ‘Harmonized’ implies taking multiple descriptions of the same thing & agreeing on a common meaning (e.g. convulsions & grand mal)
- Need to include the multiple levels of information available (e.g. report, observation, EEG, MRI, genetic testing)
- Need to show relationships between concepts (e.g. child, staring, EEG)
- Have rules and be ‘computable’

# Past/Current classifications

---

- ILAE C & T- seizures 1981
- ILAE C & T- syndromes 1989
- Semiology (Luders)- 1999
- ILAE 2010
- ILAE Epidemiology 2010
- ICD-9, 10, (11)
- SNOMED CT

# Ontologies

---

- = formal specification of **terms** in the domain (*e.g. epilepsy*) and **relations** among them (*e.g. complex partial **is a** type of partial seizure which **is a** type of seizure*)
- Why make one?
  - Share common understanding of information
  - Enable reuse of information
  - Make assumptions explicit
  - Analyze domain knowledge



# Annotation Files and Enrichment Analysis: Gene Ontology Consortium

<http://geneontology.org/>

The screenshot shows the Gene Ontology Consortium website. A red circle highlights the 'Downloads' menu, which includes 'Overview', 'Annotations', 'Ontology', and 'Mappings'. A red arrow points from the text 'Download Gene Association Files (GAFs)' to the 'Annotations' option in the menu. Another red circle highlights the 'Enrichment analysis (beta)' section, with a red arrow pointing from the text 'Perform Enrichment Analysis' to it. The 'Enrichment analysis (beta)' section includes a search bar for 'terms and gene products', a 'Search' button, and a 'Submit' button. The 'Highlighted GO term' section features a diagram of a biological process and a text description. The 'Random FAQs' section lists several questions and answers. The 'What is the Gene Ontology?' section provides an introduction to the Gene Ontology. The 'Statistics' section is also visible. The 'WormBase' logo is at the bottom left, and a circular logo is at the bottom right.

Gene Ontology Consortium

Search GO data

terms and gene products

Search

Enrichment analysis (beta)

Your gene IDs here

biological process

C. elegans

Submit

Advanced options

Powered by RAO740R

Statistics

What is the Gene Ontology?

An Introduction to the Gene Ontology

Download Gene Association Files (GAFs)

Perform Enrichment Analysis

Highlighted GO term

Representing "phases" in GO biological process

The GOC has recently introduced a new term *biological phase* (GO:0044848), as a direct subclass of biological process. This class represents a distinct period or stage during which biological processes can occur.

Random FAQs

- How are gene products associated with GO terms?
- What is a 'gene product'?
- How do I become a member of the GO Consortium?


View all FAQs

WormBase




# GO- Relationships

(imagine same for seizure/epilepsy concepts & relationships)




# Seizure/epilepsy Ontology

---



# Connecting the dots (nodes)

---



PREDICTIVE ANALYTICS

By David W. Bates, Suchi Sarin, Lucila Chao-Machado, Arind Shah, and

## Big Data In Health Care Analytics To Identify At High-Risk And High-Cos

**ABSTRACT** The US health care system is rapidly adopting electronic health records, which will dramatically increase the quantity of clinical data that are available electronically. Simultaneously, rapid progress has been made in clinical analytics—techniques for analyzing large quantities of data and gleaning new insights from that analysis—which is part of what is known as *big data*. As a result, there are unprecedented opportunities to use big data to reduce the costs of health care in the US. We identify six use cases—that is, key examples—where such opportunities exist to reduce costs through the use of big data: (1) identifying patients at high risk of readmission, (2) identifying patients whose condition worsens), adverse events, and treatment failures, (3) identifying diseases affecting multiple organ systems. We discuss the challenges that are likely to emerge from clinical analytics, the need to obtain such insights, and the infrastructure needed to support such registries, assessment scores, monitoring devices, and so on. Organizations will need to perform the necessary changes to implement changes that will improve care while addressing findings have policy implications for regulatory oversight, ways to address privacy concerns, and the support of research on analytics.

doi:10.1093/brain/awr212

Brain 2011; 134; 2948–2959 | 2948

## BRAIN

A JOURNAL OF NEUROLOGY

## Data mining neocortical high-frequency oscillations in epilepsy and controls

Justin A. Blanco,<sup>1,2</sup> Matt Stead,<sup>3</sup> Abba Krieger,<sup>4</sup> William Stacey,<sup>5,6</sup> Douglas Maus,<sup>7</sup> Eric Marsh,<sup>8,9</sup> Jonathan Viventi,<sup>2</sup> Kendall H. Lee,<sup>10</sup> Richard Marsh,<sup>10</sup> Brian Litt,<sup>2,9</sup> and Gregory A. Worrell<sup>3</sup>

Research and applications



## Heart beats in the cloud: distributed analysis of electrophysiological 'Big Data' using cloud computing for epilepsy clinical research

Satya S Sahoo,<sup>1</sup> Catherine Jayapandian,<sup>1</sup> Gaurav Garg,<sup>2</sup> Farhad Kaffashi,<sup>3</sup> Stephanie Chung,<sup>2</sup> Alireza Bozorgi,<sup>2</sup> Chien-Hun Chen,<sup>1</sup> Kenneth Loparo,<sup>3</sup> Samden D Lhatoo,<sup>2</sup> Guo-Qiang Zhang<sup>1,3</sup>

Sahoo SS, et al. *J Am Med Inform Assoc* 2014;21:263–271.

# Big Data from an EHR

---

Biomedical Informatics Insights



CASE REPORT

**OPEN ACCESS**

Full open access to this and thousands of other papers at <http://www.la-press.com>.

## Personalizing Drug Selection Using Advanced Clinical Decision Support

John Pestian<sup>1</sup>, Malik Spencer<sup>1</sup>, Pawel Matykiewicz<sup>1</sup>, Kejian Zhang<sup>2</sup>, Sander Vinks<sup>3</sup> and Tracy Glauser<sup>4</sup>

<sup>1</sup>Clinical Linguistic Group, Division of Biomedical Informatics. <sup>2</sup>Division of Human Genetics. <sup>3</sup>Division of Clinical Pharmacology.

<sup>4</sup>Division of Neurology. Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229. Email: [john.pestian@cchmc.org](mailto:john.pestian@cchmc.org).



# Big Data from a claims database

---

56(2016) 32-37



## Changing the approach to treatment choice in epilepsy using big data

Orrin Devinsky<sup>a,\*</sup>, Cynthia Dilley<sup>b</sup>, Michal Ozery-Flato<sup>c</sup>, Ranit Aharonov<sup>c</sup>, Ya'ara Goldschmidt<sup>c</sup>,  
Michal Rosen-Zvi<sup>c</sup>, Chris Clark<sup>b</sup>, Patty Fritz<sup>b</sup>

- IMS Healthcare Surveillance Data Incorporated medical claims database
- ICD 9 codes for patient ascertainment

## What Can We Do Until Then?

---

- Adopt strategies known to reduce morbidity, mortality, and, when possible, reduce costs
- Implement meaningful, large scale data aggregation
  - Common definitions & data elements
  - Harmonize & Organize knowledge in a logical manner (ontologies)
  - Leverage the accumulated Big Data to inform personalized medicine
- Incentivize health system behavior that rewards active participation in improving outcomes for patients

# AAN-Epilepsy Update

## Performance Measure Set- 2014

---

### Epilepsy Evidence Based Processes and Desired Outcomes

The Work Group identified the following evidence based processes and desired outcomes for patients with epilepsy prior to drafting the measurement set:

Desired Outcomes:

1. Freedom from seizures
2. Reduction of seizure frequency
3. Reduced risk of death associated with seizures (e.g., sudden unexpected death in epilepsy (SUDEP), accident, or suicide)
4. Reduce and address safety issues (e.g., falls, injury, etc.)
5. Increased independence
6. Reduction of mental health and behavioral health comorbidities
7. Recognition and reduction of cognitive morbidity
8. Increased patient engagement in care and self-management
9. Referral to appropriate testing and reduction of unnecessary testing (e.g., neuroimaging, EEG, etc.)
10. Reduction of Emergency Department visits and emergency services
11. Improved quality of life
12. Reduction of cost of care
13. Improved patient experience



# AAN-Epilepsy Update

## Performance Measure Set- 2014

---

### Evidence Based Processes:

1. Timely and appropriate referrals to an epilepsy specialist for patients with refractory epilepsy
2. Early and accurate diagnosis
3. Reduction of and monitoring of anti-seizure medication side effects
4. Improved coordination of care
5. Patient centered care provided

# **CMS Quality Strategy 2013 – Beyond**

November 18, 2013

---

For Public Release

## NATIONAL QUALITY FORUM

---

### BRIEF MEASURE INFORMATION

**De.1 Measure Title:** Seizure type(s) and current seizure frequency(ies)

---

**Co.1.1 Measure Steward:** American Academy of Neurology

---

**De.2 Brief Description of Measure:** All visits for patients with a diagnosis of epilepsy who had the type(s) of seizure(s) and current seizure frequency for each seizure type documented in the medical record.

---

**2a1.1 Numerator Statement:** Patient visits with seizure type(s) specified and current seizure frequency for each seizure type documented in the medical record.

# Quality Measures for Neurologists

---

- Physician Quality Reporting System
- Started in 2007, eliminated going forward

Epilepsy

PQRS #266

## Seizure Type(s) and Current Seizure Frequency(ies)

---

*This measure is to be reported for all patients with epilepsy — at **all visits** during the reporting period for patients with a diagnosis of epilepsy.*

### Measure description

Percentage of patient visits with a diagnosis of epilepsy who had the type(s) of seizure(s) and current seizure frequency(ies) for each seizure type documented in the medical record

### What will you need to report for each patient with epilepsy for this measure?

If you select this measure for reporting, you will report:

- Whether or not you documented seizure type(s) and frequency(ies)

### What if this process or outcome of care is not appropriate for your patient?

There may be times when it is not appropriate to document seizure type and frequency, due to:

- Medical reasons (eg, patient is unable to communicate and no informant is available) OR
- Patient reasons (eg, patient and/or informant refuses to answer or comply)

In these cases, you will need to indicate which reason applies, and specify the reason on the worksheet and in the medical chart.

## PQRS- 2016

---

Measure #268 (NQF 1814): Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy  
– National Quality Strategy Domain: Effective Clinical Care

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES:

CLAIMS, REGISTRY

DESCRIPTION:

All female patients of childbearing potential (12 - 44 years old) diagnosed with epilepsy who were counseled or referred for counseling for how epilepsy and its treatment may affect contraception OR pregnancy at least once a year

## In Summary

---

- There is clearly the need to be better soon
- There needs to be outcomes that are meaningful to patients, families, payers and society
- There is the strong suggestion from other areas of medicine that organized care can produce measure improvements in outcomes
- There is a requirement for consistent, detailed data collection & analysis